NO20082181L - Formuleringer av Fispemifen - Google Patents

Formuleringer av Fispemifen

Info

Publication number
NO20082181L
NO20082181L NO20082181A NO20082181A NO20082181L NO 20082181 L NO20082181 L NO 20082181L NO 20082181 A NO20082181 A NO 20082181A NO 20082181 A NO20082181 A NO 20082181A NO 20082181 L NO20082181 L NO 20082181L
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
fispemifen
formulations
stereoisomer
metabolite
Prior art date
Application number
NO20082181A
Other languages
English (en)
Norwegian (no)
Inventor
Veli-Matti Lehtola
Kaija Halonen
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20082181L publication Critical patent/NO20082181L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
NO20082181A 2005-11-09 2008-05-13 Formuleringer av Fispemifen NO20082181L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73493505P 2005-11-09 2005-11-09
PCT/IB2006/004240 WO2007099410A2 (fr) 2005-11-09 2006-11-09 Formulations de fispemifène

Publications (1)

Publication Number Publication Date
NO20082181L true NO20082181L (no) 2008-05-27

Family

ID=38459402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082181A NO20082181L (no) 2005-11-09 2008-05-13 Formuleringer av Fispemifen

Country Status (11)

Country Link
US (1) US20070104743A1 (fr)
EP (1) EP1948148A2 (fr)
JP (1) JP2009514944A (fr)
KR (1) KR20080075157A (fr)
CN (1) CN101304738A (fr)
AU (1) AU2006339325A1 (fr)
BR (1) BRPI0618510A2 (fr)
CA (1) CA2628964A1 (fr)
NO (1) NO20082181L (fr)
RU (1) RU2008122993A (fr)
WO (1) WO2007099410A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
EP2271314A4 (fr) * 2008-03-28 2013-12-25 Univ Massachusetts Compositions et procédés de préparation de nanoémulsions
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US6261812B1 (en) * 1997-08-18 2001-07-17 Kao Corporation Process for producing diglycerides
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
EP1666033B1 (fr) * 2001-11-29 2008-12-31 GTX, Inc. Prevention et traitement de l'osteoporose induite par la privation d'androgene
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
EP1727802A1 (fr) * 2004-02-25 2006-12-06 Smithkline Beecham Corporation Derives de quinoline substitués utiles pour la modulation selective du recepteur d' estrogene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene

Also Published As

Publication number Publication date
US20070104743A1 (en) 2007-05-10
CA2628964A1 (fr) 2007-09-07
BRPI0618510A2 (pt) 2011-09-06
JP2009514944A (ja) 2009-04-09
KR20080075157A (ko) 2008-08-14
WO2007099410A3 (fr) 2008-04-17
EP1948148A2 (fr) 2008-07-30
AU2006339325A1 (en) 2007-09-07
RU2008122993A (ru) 2009-12-20
WO2007099410A2 (fr) 2007-09-07
CN101304738A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
NO20082181L (no) Formuleringer av Fispemifen
DE602005027540D1 (de) Feste formulierungen von ospemifen
NO20043367L (no) Oralt farmasoytisk preparat
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
LU92736I2 (fr) Ospémifène dans toutes les formes protégées par lebrevet de base
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
MY151295A (en) Pyrimidyl indoline compound
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
TW200606164A (en) New compounds
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
UY27969A1 (es) Formulaciones que comprenden un compuesto de indolinona
WO2009007137A3 (fr) Composition pharmaceutique pour application topique de composés difficilement solubles
TW200800984A (en) New compounds
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon
MX2013005965A (es) Nuevos compuestos de triazol iii.
NO20065074L (no) Nye orale formuleringer av ospemifen.
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
NO20054319L (no) Neovaskulaseringspromoter
GB0322994D0 (en) Organic compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application